Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

AZ claims another win for Imfinzi in frontline liver cancer

 April 2, 2026

Pharmaphorum

AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.

Clinical DataOncologyRead full story

Post navigation

ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity →
← Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com